Background: Patients with heart failure are living longer with the inevitable morbidity of rising medication counts. It remains uncertain what fraction of this ensuing polypharmacy exactly predicts adverse clinical outcomes. Methods: This prospective, cross-sectional study examined case notes and electronic records of patients admitted to Weill Cornell-affiliated tertiary medical institution (Hamad Medical Corporation, Doha, Qatar) with a confirmed echocardiographic and clinical diagnosis of heart failure between January 2018 to January 2022. Each patient's medication census for the past four months was tallied, and a definitional threshold of ≤4, ≥5, ≥10 medications was established. The primary outcome was all-cause mortality within the study period. Other secondary outcomes explored include the number of heart failure-related admissions, the average length of stay, and the need for intensive care unit admission. Results: Out of a total of 7354 patients included in the study, 70% were males with a median age of 59 years (interquartile range [IQR] 48 – 71). The median (IQR) age-adjusted Charlson Comorbidity Index (CCI) was 2 (1 – 5). A total of 1475 (20%) participants died within the study period. Patient cohorts with excessive polypharmacy (≥9 medications) comprising of both heart failure related, and general medications had the highest probability of survival up to 1.6 years compared to those with lower medication thresholds (≤4), the mortality rate decreased by 18% for patients with excessive polypharmacy (≥9 medications) [HR=0.82, 95% CI: 0.71 – 0.94]). There were no differential mortality outcomes between patients with major vs. excessive heart failure-specific polypharmacy (HR 0.95 [0.81 – 1.13], p = 0.59); and (0.74 [0.53 – 1.01], p = 0.059) for major and excessive heart failure specific polypharmacy respectively. Conversely, patients with non-heart failure-related polypharmacy had increased risks of intensive care admissions (aOR=1.78, 95% CI: 1.13 – 2.70). Heart failure patient cohorts with severe and moderate CCI had higher mortality risks (HR=1.18, 95% CI: 1.03 – 1.36) and (HR=1.38, 95%CI: 1.20 – 1.58), respectively, compared to those with mild index. Conclusion: In an examination of a real-world database of patients with chronic heart failure, major non-heart failure-related polypharmacy was associated with an increased risk of intensive care admissions. Excessive polypharmacy (≥9 medications) comprising both heart failure and non-heart failure-related medications was associated with increased rates of survival. This necessitates the need for a more nuanced approach by directing intervention measures at the non-heart failure medication fraction of polypharmacy in these cohorts of patients. Funding: This study was funded by the grant from the medical research center Hamad Medical Corporation, Doha Qatar (MRC-01-21-937). Declaration of Interests: None of the authors has any conflict of interest to declare Ethics Approval: The study Protocol and relevant documentation for access to patient level data for the study was submitted for review to the independent review Board of medical research center Hamad Medical Corporation, Doha Qatar, following which approval given to proceed with the study (MRC-01-21-937)